Insights & news

Fourth Agreement for Supply of COVID-19 Vaccine between European Commission and BioNTech - Pfizer Alliance

  • 12/11/2020
  • Articles

As part of its European Vaccines Strategy adopted in June 2020 (see, Van Bael & Bellis Life Sciences News Alert of 18 June 2020), the European Commission (the Commission) announced on 11 November 2020 that it approved a fourth agreement providing for access to a potential vaccine against Covid-19 (see, attached press release).
The Commission’s partner for this agreement is an alliance between BioNTech and Pfizer. The parties agreed on an initial purchase of 200 million doses and on an option for the Commission to request a further 100 million doses that will be supplied once the vaccine is demonstrably safe and effective against Covid-19. If it secures a European marketing authorisation, the vaccine will ultimately end up in the hands of interested EU Member States which will have the possibility to donate the vaccine to lower and middle-income countries or redirect it to other European countries.
The vaccine has elicited significant enthusiasm following the publication on 9 November 2020 of initial trial results involving 94 cases. These indicated a vaccine efficacy rate of more than 90% at 7 days after administration of the second dose (the vaccination consists of a 2-dose schedule).
The agreement follows similar deals with AstraZeneca, Sanofi-GSK and Janssen Pharmaceutica (see, Van Bael & Bellis Life Sciences News Alert of 31 August 2020; Van Bael & Bellis Life Sciences News Alert of 21 September 2020; and Van Bael & Bellis Life Sciences News Alert of 12 October 2020). The Commission also concluded exploratory talks with CureVac and Moderna.


Key contacts

Related practice areas

Related insights

Sign up for updates
    • 27/11/2020
    • Articles

    European Commission Fines Cephalon and Teva On Account of "Pay-for-Delay" Patent Settlement Agreement

    On 26 November 2020, the European Commission (the Commission) brought to an end a long running competition case by finding against Cephalon and Teva on account of a “pay-for-delay” patent settlement agreement involving modafinil, the active substance of a sleeping disorder medicine (see, attached Commission press release).

    Read more
    • 26/11/2020
    • Articles

    European Commission Presents Pharmaceutical Strategy for Europe

    On 25 November 2020, the European Commission (the Commission) unveiled its Pharmaceutical Strategy for Europe (PSE), a wide-ranging document that discusses a series of broad policy statements, tentative considerations and concrete measures to tackle the many challenges faced by the pharmaceutical sector and its diverse stakeholders (see, attached Commission Communication (2020) 761 final; Commission press release; and Commission Q&A). The announcement follows an extensive period of consultation, study and preparation (see, Van Bael & Bellis Life Sciences News Alerts of 20 October 2020; 12 August 2020; 17 June 2020; 3 June 2020; and 28 May 2020).

    Read more
    • 25/11/2020
    • Articles

    Potential Covid-19 Vaccine Supplier Moderna Sixth Contract Partner of European Commission

    On 24 November 2020, European Commission President von der Leyen released a statement announcing that she would approve a sixth agreement with a supplier of a potential Covid-19 vaccine (see, attachment). The Commission’s new contract partner is Moderna. Under the agreement, the Commission will have the right to buy up to 160 million doses of the vaccine, if and when that product obtains a marketing authorisation from the European Medicines Agency. In recent days, the Commission announced similar deals with CureVac (see, Van Bael & Bellis Life Sciences News Alert of 17 November 2020) and with BioNTech and Pfizer (see, Van Bael & Bellis Life Sciences News Alert of 12 November 2020). The Commission President suggested that a seventh agreement is being negotiated which paves the way for the creation in Europe of “one of the most comprehensive COVID-19 vaccine portfolios in the world”.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *